Month: August 2022

• Myriad Genetics’ EndoPredict test accurately identified premenopausal women with ER+, HER2- breast cancer who could safely avoid adjuvant chemotherapy

SALT LAKE CITY, Aug. 31, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today Clinical Cancer Research, a journal of the American Association for Cancer Research, published a study ¹ that shows the EndoPredict^® breast cancer prognostic test significantly predicted distant recurrence in premenopausal women with ER+, HER2- early-stage breast cancer. This newly published study represents the first clinical validation of EndoPredict in a solely premenopausal population.

The study — first presented in an abstract at the 2021 ASCO Annual Meeting by Anastasia Constantinidou et al² — examined tumor samples from 385 premenopausal women with ER+, HER2- primary breast cancer who had not received chemotherapy. The results show EndoPredict accurately identified premenopausal women with and without affected lymph nodes who could safely avoid adjuvant chemotherapy as part of their treatment plans due to a very low recurrence risk.

“This important publication on the new EndoPredict data demonstrates our ongoing commitment to advance precision medicine for patients with breast cancer,” said Dr. Ralf Kronenwett, director of International Medical Affairs, Myriad Genetics. “In light of mounting clinical recommendations to reduce overtreatment in breast cancer, the results are particularly encouraging. With around a third of all new breast cancer cases occurring in patients aged 54 or younger³, using EndoPredict among premenopausal women provides important insights to inform personalized treatment, including whether there’s a benefit to using chemotherapy or not.”

The study shows that patients with EndoPredict low-risk scores had a 97% distant recurrence free survival (DRFS) versus 76% for high-risk patients. Importantly, 19% of node-positive premenopausal patients had EndoPredict low-risk scores with 100% DRFS and were able to safely avoid chemotherapy and continue onto endocrine therapy alone.

Another key result from an exploratory subgroup analysis within the study found similar DRFS rates in low-risk patients with or without ovarian function suppression (OFS), with less than 5% distant recurrence after 10 years in both groups.

“This important study shows that premenopausal patients with a low-risk EndoPredict score have a good long-term outcome without chemotherapy and may be considered for treatment with endocrine therapy only,” said Dr. Anastasia Constantinidou, Bank of Cyprus Oncology Centre and Cyprus Cancer Research Institute. “These findings are relevant to better inform personalized treatment decisions for a large proportion of premenopausal women with ER+, HER2- early-stage breast cancer.”

About the study
EndoPredict is a prognostic test that predicts patient risk of breast cancer recurrence to help identify who can consider safely forgoing chemotherapy. It analyzes 12 genes to create a molecular score, which is combined with tumor features, such as tumor size and nodal status, to establish a patient risk score (EPclin).

The Clinical Validation of EndoPredict in Premenopausal Women study tested tumor samples from 385 premenopausal women with ER+, HER2- primary breast cancer (pT1-3, pN0-1) who did not receive chemotherapy in addition to endocrine therapy. All samples were retrospectively tested blinded to clinical and outcome data with EndoPredict. Associations of EPclin Risk Scores with 10-year DRFS were evaluated by Cox proportional hazards models and Kaplan-Meier analysis. The primary outcome was 10-year DRFS.

In addition to EPclin, clinical variables of interest included age at diagnosis, tumor size, tumor grade, nodal status, Ki 67 expression, and continuous estrogen receptor (ER) expression and progesterone receptor (PgR) expression.

More information about this study can be found here.

¹ Constantinidou et al. Clin Cancer Res 2022 (https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-22-0619/708058/Clinical-Validation-of-EndoPredict-in)
² Constantinidou et al 2021 ASCO (https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.537)
³ SEER Cancer Statistics Review, 1975-2016. Bethesda, MD: National Cancer Institute;2019.

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the World’s Most Innovative Companies for 2022. For more information, visit www.myriad.com.

Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. All rights reserved.

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to using EndoPredict among premenopausal women to provide important insights to inform personalized treatment, including whether there’s a benefit to using chemotherapy or not. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 25, 2022, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.

COPENHAGEN, Denmark, Aug. 31, 2022 (GLOBE NEWSWIRE) — Copenhagen Infrastructure Partners (CIP) has reached final close on its new fund, CI Energy Transition Fund I (CI ETF I). The fund was oversubscribed and closed at the hard cap of EUR 3 billion. This makes CI ETF I the largest dedicated clean hydrogen fund globally.

CI ETF I achieved commitments from investors across the Nordics (~25% of commitments), Europe (~45%), Asia-Pacific (~20%) and North America (~10%) with approximately a 50/50 split between existing investors in CIP funds and new investors. The fund’s investor base comprises approximately 65 institutional investors, primarily pension funds, life insurance companies, sovereign wealth funds, asset managers, and family offices.

“We are very pleased to welcome a prominent group of existing and new institutional investors to CI ETF I and are delighted that investors share our confidence in and appetite for clean energy infrastructure projects and invest alongside CIP in the next phase of the energy transition. Solutions such as Power-to-X will be key for countries and industries to take the next big leap within reaching the commitments of the Paris agreement and achieving energy independence. As an industry pioneer and one of the global market leaders in greenfield renewable infrastructure investments, CIP is uniquely positioned to invest in this segment,” says Jakob Baruël Poulsen, Managing Partner in CIP.

CI ETF I will invest in next generation renewable energy infrastructure including industrial scale Power-to-X (PtX) projects and enables institutional investors to participate in the decarbonization of the so-called hard to abate industries and support the further integration of renewable power generation in the energy mix through grid balancing. The fund will primarily focus on greenfield projects in the OECD and aims to contribute to the decarbonization of industries such as agriculture, aviation, shipping, chemical manufacturing, and steel production through the use of green fuels and feedstock and CO2-free fertilizers.

CI ETF I make up an integral part of CIP’s distinct fund strategies that tap into the main renewable energy transition trends. The fund will apply the same and proven value creation and de-risking approach as CIP’s existing funds, though with a focus for CI ETF on PtX. CI ETF I will apply CIP’s industrial skills to optimize and de-risk its projects through among others project design, partner selection, and contracting. Once de-risked the projects are expected to have core infrastructure characteristics including long term offtake contracts.

CI ETF I is off to a strong start with FID taken on one investment and ownership on several attractive industrial scale development stage PtX projects with diverse exposure to production technologies and offtake markets. The projects which among others are in Western Europe (Denmark, Norway, Spain, Portugal), South America (Chile), and Australia are expected to produce green hydrogen, green ammonia, and sustainable aviation fuel based on GW scale renewable energy production and electrolysis capacity.

CI ETF I’s current portfolio once operational is estimated to reduce more than 7.5 million tonnes of CO2 annually (or the equivalent to removing ~1.6 million cars from the roads permanently) and deliver more than 4 million tonnes of green fuels each year.

For the marketing of CI ETF I, law firms Plesner and Clifford Chance acted as legal counsel, KPMG Acor Tax as tax advisor, and Selinus Capital Advisors, Compagnie Financière Jacques Coeur (CFJC) and Allen Partners as placement agents.

About Copenhagen Infrastructure Partners
Founded in 2012, Copenhagen Infrastructure Partners P/S (CIP) today is the world’s largest dedicated fund manager within greenfield renewable energy investments and a global leader in offshore wind. The funds managed by CIP focuses on investments in offshore and onshore wind, solar PV, biomass and energy-from-waste, transmission and distribution, reserve capacity, storage, advanced bioenergy, and Power-to-X.

CIP manages ten funds and has to date raised approximately EUR 19 billion for investments in energy and associated infrastructure from more than 135 international institutional investors. CIP will accelerate its role in the global energy transition and aim to have EUR 100 billion under management in green energy investments in 2030. CIP has approximately 340 employees and offices in Copenhagen, London, Hamburg, Utrecht, New York, Tokyo, Singapore, Seoul, and Melbourne. For more information, visit www.cip.dk

For further information, please contact:

Simon Augustesen, – VP, Chief Communication and Marketing Officer, Phone: +45 30526721, Email: siau@cip.dk

Thomas Kønig, Partner – Investor Relations, Phone: +45 7070 5151, Email: tkon@cip.dk